Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $19.32.
Several equities analysts have commented on FOLD shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, February 5th. ValuEngine lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Citigroup upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 target price on the stock in a report on Wednesday, January 16th. Finally, BidaskClub upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th.
In related news, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $12.12, for a total value of $242,400.00. Following the transaction, the chief executive officer now directly owns 688,081 shares of the company’s stock, valued at approximately $8,339,541.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 103,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $11.71, for a total value of $1,211,985.00. Following the completion of the transaction, the chief executive officer now directly owns 771,581 shares in the company, valued at $9,035,213.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,769 shares of company stock worth $2,520,371. 2.90% of the stock is owned by company insiders.
NASDAQ FOLD traded up $0.17 on Friday, reaching $11.14. The stock had a trading volume of 139,937 shares, compared to its average volume of 3,146,604. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.12 and a quick ratio of 9.03. Amicus Therapeutics has a 1-year low of $8.27 and a 1-year high of $17.62. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -3.84 and a beta of 1.77.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
